Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 40 of 40 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
EML4 - ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Alectinib	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).	26849637
EML4 - ALK ALK G1269A	lung non-small cell carcinoma	resistant		Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated stable disease when treated with Xalkori (crizotinib), but then progressed, and was found to harbor a secondary resistance mutation, ALK G1269A (PMID: 22235099).	22235099
EML4 - ALK ALK G1269A	lung adenocarcinoma	predicted - resistant		Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK G1269A was identified at progression on Xalkori (crizotinib) in two patients with lung adenocarcinoma harboring EML4-ALK (PMID: 34058070).	34058070
EML4 - ALK ALK G1269A	lung adenocarcinoma	predicted - resistant		Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK G1269A was identified at progression on Xalkori (crizotinib) in a patient with lung adenocarcinoma harboring EML4-ALK (PMID: 38360931).	38360931
EML4 - ALK ALK G1269A	lung non-small cell carcinoma	resistant		Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK G1269A was identified in the post-progression biopsy of a patient with non-small cell lung cancer harboring EML4-ALK who was treated with Xalkori (crizotinib) (PMID: 33166721).	33166721
EML4 - ALK ALK G1269A	lung adenocarcinoma	sensitive	Brigatinib	Brigatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) treatment inhibited viability of patient-derived organoids of lung adenocarcinoma harboring EML4-ALK and ALK G1269A in culture and resulted in tumor shrinkage in a patient-derived xenograft (PDX) model (PMID: 38360931).	38360931
EML4 - ALK ALK G1269A	lung adenocarcinoma	sensitive	Ceritinib	Ceritinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) treatment inhibited viability of patient-derived organoids of lung adenocarcinoma harboring EML4-ALK and ALK G1269A in culture and resulted in tumor shrinkage in a patient-derived xenograft (PDX) model (PMID: 38360931).	38360931
EML4 - ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Alectinib	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of a Xalkori (crizotinib)-resistant human non-small cell lung cancer cell line harboring an EML-ALK fusion with ALK G1269A in culture and induced tumor regression in cell line xenograft models (PMID: 26849637, PMID: 23344087).	26849637 23344087
EML4 - ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture, and inhibited tumor growth in xenograft models (PMID: 24887559).	24887559
EML4 - ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Lorlatinib	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315).	26144315
EML4 - ALK ALK G1269A	lung non-small cell carcinoma	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines expressing ALK G1269A in the context of EML4-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24675041).	24675041
EML4 - ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).	24675041
EML4 - ALK ALK G1269A	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).	26698910
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
EML4 - ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4 - ALK ALK G1269A	Advanced Solid Tumor	resistant		ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In preclinical studies, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910).	26698910 27009859
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	AZD3463	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
EML4 - ALK ALK G1269A	Advanced Solid Tumor	predicted - resistant		Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Rozlytrek (entrectinib) compared to cells expressing wild-type EML4-ALK (PMID: 26939704).	26939704
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).	26698910
EML4 - ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).	26698910
EML4 - ALK ALK G1269A	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22235099).	22235099
EML4 - ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
EML4 - ALK ALK G1269A	Advanced Solid Tumor	resistant		ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).	25727400
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 25727400).	25727400
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 25727400).	25727400
EML4 - ALK ALK G1269A	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive		TPX-0131	Preclinical - Cell culture	Actionable	In a preclinical study, TPX-0131 inhibited proliferation of transformed cells expressing ALK G1269A in the context of EML4-ALK in culture (PMID: 34158340).	34158340
EML4 - ALK ALK G1269A	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK G1269A	Advanced Solid Tumor	predicted - resistant		Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated resistance to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 33627640).	33627640
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 33627640).	33627640
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 33627640).	33627640
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	Ceritinib	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 33627640).	33627640
EML4 - ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited viability of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 33627640).	33627640
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive		XMU-MP-5	Preclinical - Cell culture	Actionable	In a preclinical study, XMU-MP-5 treatment decreased downstream signaling and inhibited proliferation of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 34845836).	34845836
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive		Iruplinalkib	Preclinical - Cell culture	Actionable	In a preclinical study, Iruplinalkib (WX-0593) treatment inhibited viability of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 35421578).	35421578
EML4 - ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) treatment inhibited viability of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 35421578).	35421578
EML4 - ALK ALK G1269A	Advanced Solid Tumor	resistant		Ensartinib	Preclinical - Cell culture	Actionable	In a preclinical study, a cell line expressing EML4-ALK with ALK G1269A was resistant to Ensacove (ensartinib) in culture (PMID: 31446141).	31446141
EML4 - ALK ALK G1269A	Advanced Solid Tumor	predicted - sensitive		NVL-655	Preclinical - Cell culture	Actionable	In a preclinical study, NVL-655 moderately inhibited viability of cells expressing EML4-ALK and ALK G1269A in culture (PMID: 39269178).	39269178

Showing 1 to 40 of 40 entries

Filter rows:

Profile Name	EML4 - ALK ALK G1269A
Gene Variant Detail	ALK G1269A (unknown) EML4 - ALK (gain of function)
Relevant Treatment Approaches	Alectinib AZD3463 Brigatinib Ceritinib Lorlatinib

Molecular Profile Detail

Contact

Filtering

Sorting